In today’s briefing:
- GEM Weekly (18 Nov 2022): Chinese Macro and House Prices; Alibaba, TSMC, Tencent, Meituan, NetEase
- China Healthcare Weekly (Nov.18) – Central Investment Budget, Anesthetic Drugs, Insomniacs Demand
GEM Weekly (18 Nov 2022): Chinese Macro and House Prices; Alibaba, TSMC, Tencent, Meituan, NetEase
- The Global Emerging Markets weekly provides a summary of the key news and related developments impacting the largest countries and constituents of the Global Emerging Markets equity indices.
- Macro data points:Chinese industrial production, retail sales, and new home prices.
- Companies mentioned:Alibaba Group (9988 HK), Taiwan Semiconductor (TSMC) (2330 TT), Tencent (700 HK), Meituan (3690 HK), NetEase (9999 HK), Activision Blizzard (ATVI US)
China Healthcare Weekly (Nov.18) – Central Investment Budget, Anesthetic Drugs, Insomniacs Demand
- The government issued a central infrastructure investment budget of RMB26.52 billion in healthcare sector for 2022. Related leading domestic manufacturers would maintain relatively stable growth in the next 2-3 years.
- Behind the wave of import substitution of endoscopes, the demand for anesthetic drugs would also increase, which are not affected by VBP. We think this market deserves investors’ attention.
- Considering the large number of insomniacs, the resulting demand for treatment makes the insomniacs market show a good growth prospect.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
